• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adma Biologics (NQ: ADMA )

    19.37 +3.06 (+18.76%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Adma Biologics

    < Previous 1 2 3 4 5 6 7 Next >
    Buckle Up And Use Volitility To Your Advantage
    The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary. 
    Via Talk Markets
    What You Missed On Wall Street This Past Friday
    Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
    Via Talk Markets
    Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    (ADMA) - Analyzing ADMA Biologics's Short Interest
    Via Benzinga
    Key Takeaways From ADMA Biologics Analyst Ratings
    Via Benzinga
    This Is What Whales Are Betting On ADMA Biologics
    Via Benzinga
    IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
    The company reiterated its outlook for 2024 and 2025. 
    Via Investor's Business Daily
    ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
    The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly. 
    Via Investor's Business Daily
    ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
    Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET 
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA).
    Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. 
    Via Chartmill
    Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
    Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. 
    Via Chartmill
    In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
    Via Benzinga
    ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
    Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
    Via Investor's Business Daily
    Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
    Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
    Via Investor's Business Daily
    CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    ADMA Biologics Set to Join S&P SmallCap 600 Index
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
    From ADMA Biologics, Inc.
    Via GlobeNewswire
    What's Going On With ADMA Biologics Stock Monday?
    ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
    Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
    Via Investor's Business Daily
    'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
    "Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road." 
    Via Benzinga
    Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
    Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
    Via Investor's Business Daily
    Biohaven Stock Earns Relative Strength Rating Upgrade
    Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
    Via Investor's Business Daily
    SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
    A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
    Via Investor's Business Daily
    Immunome Stock Sees RS Rating Jump To 91
    Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.